Up next

How Will the Pharma Industry Perform in 2024 & the Near Term?

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Getting the latest market analysis and data

Graham Lewis 
Vice President, Global Pharma Strategy 
IQVIA

What are the key growth indicators for the global bio/pharmaceutical market in 2024 and over the next several years, and how will the industry perform over this time?  That is the trillion-dollar question for the bio/pharma industry.

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing valuable market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharma market analysis, will provide the latest market data and trends.

COVID-19 vaccines and therapeutics had been a boon for the industry, but with lower growth for these products, how will the industry perform relative to pre-pandemic growth trends? Is the industry’s performance trending upward or not? The program will examine the growth prospects and factors influencing performance for: innovator and generic drugs; leading therapeutic sectors, both pipelines and commercial products; and developed and emerging markets.

Daniel Cohen 
Managing Director & Global Head of Pharma Outsourcing Investment Banking
Morgan Stanley

A CMDO/CMO financial outlook
The performance of the industry as a whole is a factor in determining the health of the market for pharmaceutical outsourcing, which is further influenced by other factors. The program will also feature a Wall Street view of the CDMO/CMO sector, with Daniel Cohen, Managing Director & Global Head of Pharma Outsourcing Investment Banking, Morgan Stanley, providing a financial overview of the CDMO/CMO sector: performance & investor valuations. He will provide an analysis of key mergers & acquisitions and other trends impacting sector performance.

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 18, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for pre-program networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM. 

Information on the program, including how to register, may be found here.

Recent Feature Articles

DCAT Week in Review: A Snapshot View of DCAT’s Education Programs

By
The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.

Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron

By
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).

What is Top of the Industry’s Sustainability Agenda in 2026?

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

Change, Change, & Change: The Pharma Industry’s Outlook & Response

By
The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry.